Table 3.
Univariate and multivariate analyses of HER2 positivity and patient outcome (time to recurrence in the urinary bladder)
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| HR | (95% CI) | p value | HR | (95% CI) | p value | ||
| HER2 positivity | 2.19 | (1.07-4.51) | 0.0325 | 3.70 | (1.54-8.87) | 0.0034 | |
| Sex (female vs. male) | 0.76 | (0.41-1.38) | 0.3625 | 0.75 | (0.39-1.46) | 0.4003 | |
| Age (≥70 vs. <70) | 0.79 | (0.47-1.35) | 0.3959 | 0.60 | (0.33-1.10) | 0.0994 | |
| Side (right vs. left) | 1.09 | (0.65-1.82) | 0.7563 | 1.02 | (0.59-1.79) | 0.9395 | |
| Tumor location (ureter vs. renal pelvis) | 1.36 | (0.81-2.29) | 0.2513 | 1.45 | (0.79-2.67) | 0.2347 | |
| Tumor architecture (sessile vs. papillary) | 0.82 | (0.44-1.51) | 0.517 | 0.78 | (0.36-1.69) | 0.5212 | |
| Histological grade (Grade 1, 2 vs. Grade 3) | 0.70 | (0.42-1.18) | 0.1818 | 0.34 | (0.14-0.83) | 0.0173 | |
| Concomitant carcinoma in situ (present vs. absent) | 0.99 | (0.58-1.67) | 0.9637 | 1.53 | (0.78-3.02) | 0.2187 | |
| Tumor stage (pT3-pT4 vs. pTa-pT2) | 0.92 | (0.54-1.55) | 0.7433 | 1.00 | (0.34-2.94) | 0.3399 | |
| Lymphovascular invasion (present vs. absent) | 1.24 | (0.73-2.09) | 0.4317 | 1.65 | (0.68-4.03) | 0.2719 | |
| Lymph node metastasis (present vs. absent) | 1.30 | (0.62-2.76) | 0.4874 | 2.24 | (0.85-5.90) | 0.1040 | |
CI, confidence interval; HR, hazard ratio.